

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload
NEWS 8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS 9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS 10	Aug 23	In-process records and more frequent updates now in MEDLINE
NEWS 11	Aug 23	PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12	Aug 23	Adis Newsletters (ADISNEWS) now available on STN
NEWS 13	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS 14	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS 15	Oct 09	Number of Derwent World Patents Index updates increased
NEWS 16	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 17	Oct 22	Over 1 million reactions added to CASREACT
NEWS 18	Oct 22	DGENE GETSIM has been improved
NEWS 19	Oct 29	AAASD no longer available
NEWS 20	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS 21	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS 22	Nov 29	COPPERLIT now available on STN
NEWS 23	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS 24	Nov 30	Files VETU and VETB to have open access
NEWS 25	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS 26	Dec 10	DGENE BLAST Homology Search
NEWS 27	Dec 17	WELDASEARCH now available on STN
NEWS 28	Dec 17	STANDARDS now available on STN
NEWS 29	Dec 17	New fields for DPCI
NEWS 30	Dec 19	CAS Roles modified
NEWS 31	Dec 19	1907-1946 data and page images added to CA and Caplus
NEWS EXPRESS		August 15 CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:53:22 ON 28 DEC 2001

=> file medline, uspatful, dgene, embase, scisearch, wpids, jiscst, japio, wpix, fsta, frosti, agricola, toxlit

'JISCST' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):jicst

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	0.30

FILE 'MEDLINE' ENTERED AT 16:54:13 ON 28 DEC 2001

FILE 'USPATFULL' ENTERED AT 16:54:13 ON 28 DEC 2001

CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 16:54:13 ON 28 DEC 2001

COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 16:54:13 ON 28 DEC 2001

COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:54:13 ON 28 DEC 2001

COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'WPIDS' ENTERED AT 16:54:13 ON 28 DEC 2001

COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JICST-EPLUS' ENTERED AT 16:54:13 ON 28 DEC 2001

COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'JAPIO' ENTERED AT 16:54:13 ON 28 DEC 2001

COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'WPIX' ENTERED AT 16:54:13 ON 28 DEC 2001

COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'FSTA' ENTERED AT 16:54:13 ON 28 DEC 2001

COPYRIGHT (C) 2001 International Food Information Service

FILE 'FROSTI' ENTERED AT 16:54:13 ON 28 DEC 2001

COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'AGRICOLA' ENTERED AT 16:54:13 ON 28 DEC 2001

FILE 'TOXLIT' ENTERED AT 16:54:13 ON 28 DEC 2001

=> s retro-inverted peptide

L1 28 RETRO-INVERTED PEPTIDE

=> d l1 ti abs ibib tot

L1 ANSWER 1 OF 28 USPATFULL

TI Retro-, inverso- and retro-inverso synthetic peptide analogues
AB Synthetic peptide antigen analogues of native peptide antigens with partial or complete retro, inverso or retro-inverso modifications are provided. When administered as an immunogen to an immunocompetent host the synthetic peptide antigen analogues induce the production of antibodies which recognize the native peptide antigen. Uses of these analogues, vaccines and methods of preparing vaccines comprising these antigen analogues, and antibodies generated using these antigen analogues are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:111840 USPATFULL
TITLE: Retro-, inverso- and retro-inverso synthetic peptide analogues
INVENTOR(S): Comis, Alfio, Bossley Park, Australia
Tyler, Margaret Isabel, Turramurra, Australia
Fischer, Peter, Oslo, Norway
PATENT ASSIGNEE(S): Deakin Research Limited, New South Wales, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6261569	B1	20010717
	WO 9405311		19940317
APPLICATION INFO.:	US 1997-909551		19970812 (8)
	WO 1993-AU441		19930827
			19950424 PCT 371 date
			19950424 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation of Ser. No. US 387932, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1992-4374	19920827
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Allen, Marianne P.	
ASSISTANT EXAMINER:	Zeman, Mary K.	
LEGAL REPRESENTATIVE:	Howson and Howson	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	1585	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 28 USPATFULL

TI Retro-inverso analogues of thymopentin and the method for their synthesis
AB New analogues of thymopentin (TP5) and of its tetrapeptide fragment (TP5.sup.1-4) containing two non-contiguous retro-inverted bonds in the peptide chain are described which are of the general formula (I) ##STR1## where R is hydrogen or an acyl radical, and R.sup.1 is an --OR.sup.2 group or an ##STR2## group where R.sup.2 is a hydrogen atom or a hydrocarbon radical, and R.sup.3 is a hydrogen atom or a hydroxyl group, and the corresponding pharmaceutically acceptable salts of acid or basic addition, possess immunomodulating activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 93:46534 USPATFULL

TITLE: Retro-inverso analogues of thymopentin and the method for their synthesis

INVENTOR(S): Mariotti, Sabina, Fara Sabina, Italy
Sisto, Alessandro, Rome, Italy
Nencioni, Luciano, Poggibonsi, Italy
Villa, Luigi, Florence, Italy
Verdini, Antonio S., Monterotondo, Italy

PATENT ASSIGNEE(S): Sclavo S.p.A., Siena, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5218089		19930608
APPLICATION INFO.:	US 1991-799421		19911126 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1989-454282, filed on 21 Dec 1989, now patented, Pat. No. US 5091510		

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1988-23099	19881223
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lee, Lester L.	
ASSISTANT EXAMINER:	Davenport, A. M.	
LEGAL REPRESENTATIVE:	Hedman, Gibson & Costigan	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	906	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 3 OF 28 USPATFULL

TI Renin inhibitors having all **retro-inverted peptide** bonds

AB Renin-inhibiting peptides of the formula ##STR1## in which X represents a group of the formula ##STR2## represents hydroxyl, alkoxy having up to 8 carbon atoms, benzyloxy or a group of the formula --NR.sup.4 R.sup.5,

A, B, D and E are identical or different and in each case

represent a direct bond,

represent a radical of the formula ##STR3## in which Q1 denotes oxygen, sulphur or the methylene group

represent a grouping of the formula ##STR4## m represents a number 0, 1 or 2, and L represents a group of the formula --CH.sub.2 NR.sup.2 R.sup.3

and physiologically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 92:18951 USPATFULL

TITLE: Renin inhibitors having all **retro-inverted peptide** bonds

INVENTOR(S): Bender, Wolfgang, Wuppertal, Germany, Federal Republic of
Kinast, Gunther, Wuppertal, Germany, Federal Republic of
Knorr, Andreas, Erkrath, Germany, Federal Republic of
Stasch, Johannes-Peter, Wuppertal, Germany, Federal

PATENT ASSIGNEE(S): Federal Republic of Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5095006		19920310
APPLICATION INFO.:	US 1990-553493		19900713 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1989-3926021	19890508
	DE 1990-4004820	19900216
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wax, Robert A.	
ASSISTANT EXAMINER:	Walsh, Stephen	
LEGAL REPRESENTATIVE:	Sprung Horn Kramer & Woods	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2702	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 28 USPATFULL

TI Retro-inverso analogues of thymopentin, and their use in the preparation

of pharmaceutical compositions

AB New analogues of thymopentin (TP5) and of its tetrapeptide fragment (TP5.sup.1-4) containing two non-contiguous retro-inverted bonds in the peptide chain are described.

The new compounds, of general formula (I) ##STR1## where R is hydrogen or an acyl radical, and

R.sup.1 is an --OR.sup.2 group or an ##STR2## group where R.sup.2 is a hydrogen atom or a hydrocarbon radical, and R.sup.3 is a hydrogen atom or a hydroxyl group,

and the corresponding pharmaceutically acceptable salts of acid or basic addition, possess immunomodulating activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 92:15136 USPATFULL

TITLE: Retro-inverso analogues of thymopentin, and their use in the preparation of pharmaceutical compositions

INVENTOR(S): Mariotti, Sabina, Fara Sabina, Italy

Sisto, Alessandro, Rome, Italy

Nencioni, Luciano, Poggibonsi, Italy

Villa, Luigi, Florence, Italy

Verdini, Antonio S., Monterotondo, Italy

PATENT ASSIGNEE(S): Scalvo, S.p.A., Siena, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5091510		19920225
APPLICATION INFO.:	US 1989-454282		19891221 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1988-23099	19881223
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lee, Lester L.	

ASSISTANT EXAMINER: avenport, A.
LEGAL REPRESENTATIVE: edman, Gibson & Costigan
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 786
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 28 USPATFULL
TI Retro-inverso C-terminal hexapeptide analogues of substance P
AB New retro-inverso peptides and peptide derivatives in the form of
 analogues of C-terminal hexapeptide fragments of Substance P, which are
 pharmacologically active, possess prolonged action with time, and are
of
 general formula (I): ##STR1## they being useful as vasedilators.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 87:4926 USPATFULL
TITLE: Retro-inverso C-terminal hexapeptide analogues of
 substance P
INVENTOR(S): Verdini, Antonio S., Rome, Italy
 Viscomi, Giuseppe C., Rome, Italy
PATENT ASSIGNEE(S): ENI-Ente Nazionale Idrocarburi, Rome, Italy (non-U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4638046		19870120
APPLICATION INFO.:	US 1985-689911		19850109 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1984-19142	19840113
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Phillips, Delbert R.	
LEGAL REPRESENTATIVE:	Hedman, Gibson, Costigan & Hoare	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	406	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD
TI **Retro-inverted peptide** used to deliver
 active agents across the gastrointestinal tract to treat hypertension,
 diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
 angina pectoris -
AB This invention relates to retro-inverted peptides which specifically
bind
 to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also
 included in the invention are a **retro-inverted**
 peptide which enhances the delivery of an active agent across the
 gastrointestinal tract (GIT) into the systemic, portal or hepatic
 circulation. A composition comprising a **retro-inverted**
 peptide bound to a material comprising an active agent used to
 treat a mammalian disease or disorder is also disclosed in the
invention.
 The retro-inversion peptides target gastrointestinal tract transport
 receptors to promote in vivo uptake of active agents and/or enhance
 active agent delivery across the tract into the systemic circulation.
The
 gastrointestinal agents (containing retro-inverted peptides) are used to
 facilitate the transport of active ingredients through human or animal
 gastrointestinal tissue, from the lumen to the portal, hepatic, or
 systemic circulation. The compositions containing these agents can be

used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is the full length

HAX42

amino acid sequence.

ACCESSION NUMBER: AAB03872 peptide DGENE

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602

36p

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

Apple.

L1 ANSWER 7 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AB This invention relates to retro-inverted peptides which specifically bind

to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a **retro-inverted**

peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted**

peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the

invention.

The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation.

The

gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is the full length PAX2 amino acid sequence.

ACCESSION NUMBER: AAB03871 peptide DGENE

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602

36p

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]

L1 ANSWER 8 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention.

The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation.

The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of HAX42.

ACCESSION NUMBER: AAB03870 peptide DGENE

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602 36p

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

L1 ANSWER 9 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention.

The retro-inversion peptides target gastrointestinal tract transport

receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation.

The

gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of P31.

ACCESSION NUMBER: AAB03869 peptide DGENE

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602 36p

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

L1 ANSWER 10 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AB This invention relates to retro-inverted peptides which specifically bind

to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a **retro-inverted peptide** which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted peptide** bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention.

The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation.

The

gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of PAX2.

ACCESSION NUMBER: AAB03868 peptide DGENE

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]

36p

L1 ANSWER 11 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD
TI **Retro-inverted peptide** used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -
AB This invention relates to retro-inverted peptides which specifically
bind
to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also
included in the invention are a **retro-inverted**
peptide which enhances the delivery of an active agent across the
gastrointestinal tract (GIT) into the systemic, portal or hepatic
circulation. A composition comprising a **retro-inverted**
peptide bound to a material comprising an active agent used to
treat a mammalian disease or disorder is also disclosed in the
invention.

The retro-inversion peptides target gastrointestinal tract transport
receptors to promote in vivo uptake of active agents and/or enhance
active agent delivery across the tract into the systemic circulation.

The
gastrointestinal agents (containing retro-inverted peptides) are used to
facilitate the transport of active ingredients through human or animal
gastrointestinal tissue, from the lumen to the portal, hepatic, or
systemic circulation. The compositions containing these agents can be
used to treat or prevent mammalian, especially human, diseases or
disorders, especially hypertension, diabetes, osteoporosis, haemophilia,
anaemia, cancer, migraine, and angina pectoris. The compositions can be
administered in vivo to image selected sites or tissues, such as the
gastrointestinal tract, by using an imaging agent as the active agent.
The present sequence represents a retro-inversion used in the invention.
The sequence is a HAX42 14 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03867 peptide DGENE
TITLE: **Retro-inverted peptide** used to
deliver active agents across the gastrointestinal tract to
treat hypertension, diabetes, osteoporosis, haemophilia,
anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36p
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]

L1 ANSWER 12 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD
TI **Retro-inverted peptide** used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -
AB This invention relates to retro-inverted peptides which specifically
bind
to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also
included in the invention are a **retro-inverted**
peptide which enhances the delivery of an active agent across the
gastrointestinal tract (GIT) into the systemic, portal or hepatic
circulation. A composition comprising a **retro-inverted**

peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention.

The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation.

The

gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a retro-inversion used in the invention. The sequence is a P31 16 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03866 peptide DGENE

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602 36p

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

L1 ANSWER 13 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AB This invention relates to retro-inverted peptides which specifically bind

to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a **retro-inverted**

peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a **retro-inverted**

peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the

invention.

The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation.

The

gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a retro-inversion used in the invention. The sequence is a PAX2 15 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03865 peptide DGENE

TITLE: **Retro-inverted peptide** used to

deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N)ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36p
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]

L1 ANSWER 14 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Retro-inverted neurotrophic and analgesic peptides

AB The present invention describes retro-inverted (RI) peptides encompassing

the active neurotrophic region of saposin C stimulating neurite outgrowth

and prevent neural cell death, and also promoting increased myelination in neural cells. The retro-inverted peptides can be used for stimulating neuritogenesis or preventing cell death, for stimulating myelination or preventing demyelination, or for treating pain in mammals. The RI peptidase may be used in the treatment of Parkinson's disease, retinal neuropathy, multiple sclerosis, acute disseminated leukoencephalitis, trauma to the brain and/or spinal cord, progressive multifocal leukoencephalitis, metachromatic leukodystrophy, adrenal leukodystrophy and maldevelopment of the white matter in premature infants (periventricular leucomalacia). The major advantage of retro inverted (RI) peptides is their enhanced activity in vivo due to improved resistance to proteolytic degradation. The present sequence represents a peptide from the present invention.

ACCESSION NUMBER: AAW99841 peptide DGENE
TITLE: Retro-inverted neurotrophic and analgesic peptides
INVENTOR: O'Brien J S; White M T; Wright D E
PATENT ASSIGNEE: (MYEL-N)MYELOS NEUROSCIENCES CORP.
PATENT INFO: WO 9912967 A1 19990318 37p
APPLICATION INFO: WO 1998-US18759 19980909
PRIORITY INFO: US 1998-148030 19980903
US 1997-926015 19970909
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-229223 [19]

L1 ANSWER 15 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Retro-inverted neurotrophic and analgesic peptides

AB The present invention describes retro-inverted (RI) peptides encompassing

the active neurotrophic region of saposin C stimulating neurite outgrowth

and prevent neural cell death, and also promoting increased myelination in neural cells. The retro-inverted peptides can be used for stimulating neuritogenesis or preventing cell death, for stimulating myelination or preventing demyelination, or for treating pain in mammals. The RI peptidase may be used in the treatment of Parkinson's disease, retinal neuropathy, multiple sclerosis, acute disseminated leukoencephalitis, trauma to the brain and/or spinal cord, progressive multifocal leukoencephalitis, metachromatic leukodystrophy, adrenal leukodystrophy and maldevelopment of the white matter in premature infants (periventricular leucomalacia). The major advantage of retro inverted (RI) peptides is their enhanced activity in vivo due to improved resistance to proteolytic degradation. The present sequence represents a peptide from the present invention.

ACCESSION NUMBER: AAW99840 peptide DGENE
TITLE: Retro-inverted neurotrophic and analgesic peptides

INVENTOR: O'Brien J S; White M T; Wright D E
PATENT ASSIGNEE: (MYEL-N)MYELOS NEUROSCIENCES CORP.
PATENT INFO: WO 9912967 A1 19990318
APPLICATION INFO: WO 1998-US18759 19980909
PRIORITY INFO: US 1998-148030 19980903
US 1997-926015 19970909
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-229223 [19]

37p

L1 ANSWER 16 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Retro-inverted neurotrophic and analgesic peptides

AB The present invention describes retro-inverted (RI) peptides encompassing

the active neurotrophic region of saposin C stimulating neurite outgrowth

and prevent neural cell death, and also promoting increased myelination in neural cells. The retro-inverted peptides can be used for stimulating neuritogenesis or preventing cell death, for stimulating myelination or preventing demyelination, or for treating pain in mammals. The RI peptidase may be used in the treatment of Parkinson's disease, retinal neuropathy, multiple sclerosis, acute disseminated leukoencephalitis, trauma to the brain and/or spinal cord, progressive multifocal leukoencephalitis, metachromatic leukodystrophy, adrenal leukodystrophy and maldevelopment of the white matter in premature infants (periventricular leucomalacia). The major advantage of retro inverted (RI) peptides is their enhanced activity in vivo due to improved resistance to proteolytic degradation. The present sequence represents a peptide from the present invention.

ACCESSION NUMBER: AAW99846 peptide DGENE

TITLE: Retro-inverted neurotrophic and analgesic peptides

INVENTOR: O'Brien J S; White M T; Wright D E

PATENT ASSIGNEE: (MYEL-N)MYELOS NEUROSCIENCES CORP.

PATENT INFO: WO 9912967 A1 19990318

37p

APPLICATION INFO: WO 1998-US18759 19980909

PRIORITY INFO: US 1998-148030 19980903

US 1997-926015 19970909

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1999-229223 [19]

L1 ANSWER 17 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Retro-inverted neurotrophic and analgesic peptides

AB The present invention describes retro-inverted (RI) peptides encompassing

the active neurotrophic region of saposin C stimulating neurite outgrowth

and prevent neural cell death, and also promoting increased myelination in neural cells. The retro-inverted peptides can be used for stimulating neuritogenesis or preventing cell death, for stimulating myelination or preventing demyelination, or for treating pain in mammals. The RI peptidase may be used in the treatment of Parkinson's disease, retinal neuropathy, multiple sclerosis, acute disseminated leukoencephalitis, trauma to the brain and/or spinal cord, progressive multifocal leukoencephalitis, metachromatic leukodystrophy, adrenal leukodystrophy and maldevelopment of the white matter in premature infants (periventricular leucomalacia). The major advantage of retro inverted (RI) peptides is their enhanced activity in vivo due to improved resistance to proteolytic degradation. The present sequence represents a peptide from the present invention.

ACCESSION NUMBER: AAW99845 peptide DGENE

TITLE: Retro-inverted neurotrophic and analgesic peptides

INVENTOR: O'Brien J S; White M T; Wright D E

PATENT ASSIGNEE: (MYEL-N)MYELOS NEUROSCIENCES CORP.

PATENT INFO: WO 980967 A1 19990318
APPLICATION INFO: WO 1998-18759 19980909
PRIORITY INFO: US 1998-148030 19980903
US 1997-926015 19970909
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-229223 [19]

37p

L1 ANSWER 18 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Retro-inverted neurotrophic and analgesic peptides

AB The present invention describes retro-inverted (RI) peptides encompassing

the active neurotrophic region of saposin C stimulating neurite outgrowth

and prevent neural cell death, and also promoting increased myelination in neural cells. The retro-inverted peptides can be used for stimulating neuritogenesis or preventing cell death, for stimulating myelination or preventing demyelination, or for treating pain in mammals. The RI peptidase may be used in the treatment of Parkinson's disease, retinal neuropathy, multiple sclerosis, acute disseminated leukoencephalitis, trauma to the brain and/or spinal cord, progressive multifocal leukoencephalitis, metachromatic leukodystrophy, adrenal leukodystrophy and maldevelopment of the white matter in premature infants (periventricular leucomalacia). The major advantage of retro inverted (RI) peptides is their enhanced activity in vivo due to improved resistance to proteolytic degradation. The present sequence represents a peptide from the present invention.

ACCESSION NUMBER: AAW99844 peptide DGENE

TITLE: Retro-inverted neurotrophic and analgesic peptides

INVENTOR: O'Brien J S; White M T; Wright D E

PATENT ASSIGNEE: (MYEL-N)MYELOS NEUROSCIENCES CORP.

PATENT INFO: WO 9912967 A1 19990318

37p

APPLICATION INFO: WO 1998-US18759 19980909

PRIORITY INFO: US 1998-148030 19980903

US 1997-926015 19970909

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1999-229223 [19]

L1 ANSWER 19 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Retro-inverted neurotrophic and analgesic peptides

AB The present invention describes retro-inverted (RI) peptides encompassing

the active neurotrophic region of saposin C stimulating neurite outgrowth

and prevent neural cell death, and also promoting increased myelination in neural cells. The retro-inverted peptides can be used for stimulating neuritogenesis or preventing cell death, for stimulating myelination or preventing demyelination, or for treating pain in mammals. The RI peptidase may be used in the treatment of Parkinson's disease, retinal neuropathy, multiple sclerosis, acute disseminated leukoencephalitis, trauma to the brain and/or spinal cord, progressive multifocal leukoencephalitis, metachromatic leukodystrophy, adrenal leukodystrophy and maldevelopment of the white matter in premature infants (periventricular leucomalacia). The major advantage of retro inverted (RI) peptides is their enhanced activity in vivo due to improved resistance to proteolytic degradation. The present sequence represents a peptide from the present invention.

ACCESSION NUMBER: AAW99843 peptide DGENE

TITLE: Retro-inverted neurotrophic and analgesic peptides

INVENTOR: O'Brien J S; White M T; Wright D E

PATENT ASSIGNEE: (MYEL-N)MYELOS NEUROSCIENCES CORP.

PATENT INFO: WO 9912967 A1 19990318

37p

APPLICATION INFO: WO 1998-US18759 19980909

PRIORITY INFO: US 18-148030 19980903
US 18-926015 19970909
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1999-229223 [19]

L1 ANSWER 20 OF 28 DGENE COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Retro-inverted neurotrophic and analgesic peptides

AB The present invention describes retro-inverted (RI) peptides encompassing

the active neurotrophic region of saposin C stimulating neurite outgrowth

and prevent neural cell death, and also promoting increased myelination in neural cells. The retro-inverted peptides can be used for stimulating neuritogenesis or preventing cell death, for stimulating myelination or preventing demyelination, or for treating pain in mammals. The RI peptidase may be used in the treatment of Parkinson's disease, retinal neuropathy, multiple sclerosis, acute disseminated leukoencephalitis, trauma to the brain and/or spinal cord, progressive multifocal leukoencephalitis, metachromatic leukodystrophy, adrenal leukodystrophy and maldevelopment of the white matter in premature infants (periventricular leucomalacia). The major advantage of retro inverted (RI) peptides is their enhanced activity in vivo due to improved resistance to proteolytic degradation. The present sequence represents a peptide from the present invention.

ACCESSION NUMBER: AAW99842 peptide DGENE

TITLE: Retro-inverted neurotrophic and analgesic peptides

INVENTOR: O'Brien J S; White M T; Wright D E

PATENT ASSIGNEE: (MYEL-N)MYELOS NEUROSCIENCES CORP.

PATENT INFO: WO 9912967 A1 19990318

37p

APPLICATION INFO: WO 1998-US18759 19980909

PRIORITY INFO: US 1998-148030 19980903

US 1997-926015 19970909

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1999-229223 [19]

L1 ANSWER 21 OF 28 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

TI **Retro-inverted peptide** used to deliver

active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraines and angina pectoris.

AN 2000-400037 [34] WPIDS

AB WO 200031123 A UPAB: 20000718

NOVELTY - A **retro-inverted peptide** (I) or a derivative of it, which specifically binds to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a **retro-inverted peptide** (II) which enhances delivery of an active agent across the gastro-intestinal tract into the systemic, portal or hepatic circulation;

(2) a composition, comprising (I) or (II), bound to a material comprising an active agent used to treat a mammalian disease or disorder;

(3) a composition, comprising a chimeric protein bound to a material comprising an active agent used to treat a mammalian disease or disorder, the protein comprises ZElan 144, ZElan 145 or ZElan 146, or a binding portion of them fused via a covalent bond to a second protein;

(4) a composition, comprising (I) or (II) bound to a drug containing particle;

(5) a pharmaceutical composition, comprising the composition of (2) in a carrier for use in vivo in humans;

(6) an antibody, or a fragment of it, capable of immunospecifically binding (I) or (II);

(7) a composition comprising (I) or (II) coated onto, absorbed onto or covalently bonded to, the surface of a nano- or microparticle; and

(8) a nano- or microparticle formed from (I) or (II).

ACTIVITY - Hypotensive; antidiabetic; osteopathic; hemostatic; antianemic; cytostatic; antimigraine; antianginal.

MECHANISM OF ACTION - The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation.

USE - The gastrointestinal agents are used to facilitate transport of

active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation (claimed). The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraine, and angina pectoris (claimed). The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent.

The antibodies can be used for imaging peptides after in vivo administration, to monitor treatment efficacy, to measure peptide levels in physiological samples, and in diagnostic methods.

ADVANTAGE - None given.

Dwg. 0/2

ACCESSION NUMBER: 2000-400037 [34] WPIDS

DOC. NO. CPI: C2000-120829

TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraines and angina pectoris.

DERWENT CLASS: B04

INVENTOR(S): O'MAHONY, D J

PATENT ASSIGNEE(S): (ELAN-N) ELAN CORP PLC

COUNTRY COUNT: 91

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000031123	A2	20000602	(200034)*	EN	36
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES					
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS					
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000011744	A	20000613	(200043)		
EP 1131344	A2	20010912	(200155)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT					
RO SE SI					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000031123	A2	WO 1999-IE117	19991119
AU 2000011744	A	AU 2000-11744	19991119
EP 1131344	A2	EP 1999-972640	19991119
		WO 1999-IE117	19991119

FILING DETAILS:

PATENT NO	KIND	PATENT NO
-----------	------	-----------

PRIORITY APPLN. INFO: US 1998-109038P 19981119

L1 ANSWER 22 OF 28 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Retro-inverted tri peptide cpds. - useful as hypotensive tranquillising
and analgesic agents.

AN 1986-286129 [44] WPIDS

AB EP 199379 A UPAB: 19930922

Tripeptides with at least a **retro-inverted peptide** bond, pharmaceutically acceptable basic salts, esters or alkyl amides, of formula (I) are new (where Q1 and Q2 = -CONH- or -NHCO-, at least 1 being -NHCO-; R1 is H, 1-7C alkyl, aryl, hydroxyalkyl, hydroxyarylalkyl, guanidylalkyl, aminoalkyl, alkoxyalkyl, acylaminoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl, alkylmercaptoalkyl, carbamoylalkyl, carboxyalkyl, alkylcarbamoylalkyl or alkoxy-carbonylalkyl; R2 is p-hydroxybenzyl, benzyl or a gp. of formula (II); Z is OH, OR3, NH2 or NHR3; and R3 is 1-10C alkyl).

USE/ADVANTAGE - (I) are retro-inverse analogues of Glp-Leu-Trp-OH with hypotensive, tranquilliser and analgesic activities and with reduced tendency to inactivation by circulating peptidase enzymes. Hypotensive doses are e.g. 0.1-400, pref. 2-300 mg/kg/day, pref. in 2-4 units. Admin. may be p.o. or parenterally.

0/0

ABEQ EP 199379 B UPAB: 19930922

Tripeptide with at least a retro-inverted peptidic bond, its pharmaceutically acceptable basic salts, esters or alkyl amides, definable

by means of the following general formulae; Ia, Ib, Ic; R1 represents a hydrogen atom, an alkyl group with a maximum of 7 carbon atoms, an aryl,

hydroxyalkyl or hydroxyarylalkyl, guanidylalkyl, amino-alkyl, alkyloxy-alkyl, acylamino-alkyl, imidazolylalkyl, indolyl-alkyl, mercapto-alkyl, alkylmercaptoalkyl, carbamoylalkyl, carboxyalkyl, alkyl-carbamoylalkyl or alky-loxy-carbonylalkyl group; R2 represents a

gp.

(i), (ii) or (iii) group; Z represents an OH, OR3, NH2, NHR3 group, wherein R3 represents an alkyl group with a number of carbon atoms comprised within the range of from 1 to 10.

ABEQ US 4748155 A UPAB: 19930922

Tripeptides of formulae (I), (II) and (III) are claimed, where R1 is -CH2-CH(CH3)2, -CH(CH3)2 or -CH(CH3)CH2CH3; R2 is (p-hydroxy)benzyl or a gp. of formula (IV), and Z is OH, OR3 NH2, or NHR3, where R3 is 1-10C alkyl.

USE/ADVANTAGE - (I) is used to treat hypertension, anxiety and pain. They are less labile than prior tripeptides used for this purpose.

ACCESSION NUMBER: 1986-286129 [44] WPIDS

DOC. NO. CPI: C1986-123788

TITLE: Retro-inverted tri peptide cpds. - useful as hypotensive tranquillising and analgesic agents.

DERWENT CLASS: B05

INVENTOR(S): DELUCA, G; DISTAZIO, G; POLITI, V; SISTO, A; VERDINI, A S; VIRDIA, A

PATENT ASSIGNEE(S): (ENIE) ENIRICERCHE SPA; (POLI-N) POLIFARMA SPA

COUNTRY COUNT: 7

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 199379	A	19861029	(198644)*	EN	18
R: DE FR GB					
JP 61233665	A	19861017	(198648)		

US 4748155 A 880531 (198824)
 EP 199379 B 901003 (199040)
 R: DE FR GB
 IT 1184164 B 19871022 (199041)
 DE 3674623 G 19901108 (199046)
 JP 06088968 B2 19941109 (199443) 13

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 199379	A	EP 1986-200345	19860307
JP 61233665	A	JP 1986-59653	19860319
US 4748155	A	US 1986-838120	19860310
JP 06088968	B2	JP 1986-59653	19860319

FILING DETAILS:

PATENT NO	KIND	PATENT NO
JP 06088968	B2 Based on	JP 61233665

PRIORITY APPLN. INFO: IT 1985-19961 19850319

L1 ANSWER 23 OF 28 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
 TI New retro-inverted analogues of bradykinin potentiator penta peptide -
 useful as prolonged action antihypertensives and diagnostic agents.
 AN 1986-198158 [31] WPIDS
 AB EP 185433 A UPAB: 19930922
 Retro-inverted peptides of formula (I) useful as anti-hypertensives and
 diagnostics are new. R2, R3 = D-amino acid residues; R1 = side-chain of
 an amino acid residue present in a natural peptide or its analogue; A = H,
 1-7C alkyl, aryl, aralkyl or hydroxyalkyl; B = H, 1-7C alkyl, aryl,
 aralkyl, or OH-, guanidyl-, amino-, alkoxy-, acylamino-, imidazolyl-,
 indolyl-, SH-, alkylthio-, CONH2-, COOH-, alkylcarbonyl or
 alkoxy carbonyl-alkyl; or A+B = (CH2)m, in which one of the C atoms is
 directly bonded to PhCH2O or PhS; m = 3 or 4; Z = OH, alkoxy or NH2.
 (I) in which R1 = Me, R2 = D-Phe, R3 = D-Lys and NA-CHB-COZ =
 Pro(4-allo-S-Ph)-OH, in (S)- or (R)-forms, is specifically claimed.
 USE/ADVANTAGE - (I) are analogues of bradykinin potentiator
 pentapeptide and they inhibit angiotensin-converting enzyme and have more
 prolonged activity in vivo. They are therefore useful as
 antihypertensives
 and diagnostic agents.
 0/0
 ABEQ US 4713367 A UPAB: 19930922
 Partially retroinverso peptides of formula (I), analogues of bradykinin
 potentiating peptide (BPPalpha), and salts are new. In (I), R1 and R2 are
 each the side chain of one of corresp natural peptides; X is -X-Ph or
 O-CH2-PH; Z is OH, alkoxy, NH2. Pref cpds are Glp-Lys-gPhe-mAla Pro
 (4-allo-S-Ph)-OH and Glp-Lys-gPhe-m(S) Ala-Pro (4-allo-S-Ph)-OH. (I) may
 be prepd e.g. by condensing N-mono-acetylated gem diamine cpd (II) with
 peptide (III).
 USE - (I) are more stable angiotensin-converting enzyme inhibitors
 than natural ACE inhibitor and are used as antihypertensives at dosage
 e.g. 1-1000(2.5-100) mg/day.
 ABEQ US 4728725 A UPAB: 19930922
 Retro-inverted peptide analogues of
 Bradykinin Potentiator Pentapeptide (BPP5a) of formula (I) are new.
 In (I), R3 is D-Lys; R2 is D-Phe; R1 is natural peptide amino acid
 side chain; A and B together are (CH2)m residue forming ring with bonded
 N or C atoms and with one C of (CH2)m-bridge directly bonded to O-Bz or

S-Ph; m is 3 or 4 and Z is OH, alkylOH or NH2.

Esp. cpds. (Ia) and (Ib). (I) may be prep. e.g. by liq. phase condensation of (II) with (III) using condensation agents.

USE - (I) are mixed inhibitors of ACE, recognising both C and N terminals, the retro-inversion giving increased stability against peptidases, and are used as highly active antihypertensives and diagnostics.

ACCESSION NUMBER: 1986-198158 [31] WPIDS
DOC. NO. CPI: C1986-085243
TITLE: New retro-inverted analogues of bradykinin potentiator penta peptide - useful as prolonged action antihypertensives and diagnostic agents.
DERWENT CLASS: B03 P24
INVENTOR(S): SISTO, A; VERDINI, A S; VIRDIA, A
PATENT ASSIGNEE(S): (ENIE) ENICHEM SPA; (ENIR-N) ENIRECERCHE SPA; (VEDU-N) VERDUCCI G SRL; (VERD-N) VERDUCCI SRL G
COUNTRY COUNT: 13
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 185433	A	19860625	(198631)*	EN	8
R: AT BE CH DE FR GB IT LI LU NL SE					
FR 2575048	A	19860627	(198632)		
JP 61155395	A	19860715	(198634)		
JP 62501610	W	19870702	(198732)		
US 4713367	A	19871215	(198806)		
US 4728725	A	19880301	(198812)		
IT 1178789	B	19870916	(199035)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 185433	A	EP 1985-202099	19851218
JP 61155395	A	JP 1985-289135	19851221
US 4713367	A	US 1986-821449	19860122
US 4728725	A	US 1985-811487	19851220

PRIORITY APPLN. INFO: IT 1984-24200 19841221

L1 ANSWER 24 OF 28 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Totally solid phase synthesis of peptide(s) - contg. **retro-inverted peptide** bond, using crosslinked sarcosinyl copolymer as support.

AN 1984-012770 [03] WPIDS

AB EP 97994 A UPAB: 19930925

The support comprises polydimethylacrylamide -co-acryloylsarcosine methyl ester crosslinked with N,N'-ethylene bis-acrylamide. The polypeptide (I) chain is constructed, starting from the C terminus, by condensation with amino acid and/or peptide derivs. and cpds. of formula (II) (Z and Z' are side chains present in naturally-occurring amino acids).

The cpd. I, I-bis(trifluoroacetyl) iodobenzene (III) is then used to convert terminal prim. carboxyamido gps. to amino, and finally the entire peptide is released from the resin simultaneous with removal of amine and side chain protecting gp.

Esp. the method is used to make cpd. PyroGlu-Phe-gPhe-mGly -Leu-Met-NH2 (Ia) (gPhe is gem-diaminophenylalanyl; mGly is malonyl).

Since (III) converts amido gps. on the resin, the synthesis can be done entirely in the solid phase. The method is simple and rapid; suitable

for automation and avoids the losses associated with usual isolation and purification stages. (I) have biological activity equal or better than

tht

of their natural analogues and will improved resistance to enzymatic hydrolysis.

0/0

ABEQ EP 97994 B UPAB: 19930925

The support comprises polydimethylacrylamide -co-acryloylsarcosine methyl ester crosslinked with N,N'-ethylene bis-acrylamide. The polypeptide (I) chain is constructed, starting from the C terminus, by condensation with amino acid and/or peptide derivs. and cpds. of formula (II) (Z and Z' are side chains present in naturally-occurring amino acids).

The cpd. I, I-bis(trifluoroacetyl) iodobenzene (III) is then used to convert terminal prim. carboxamide gps. to amino, and finally the entire peptide is released from the resin simultaneous with removal of amine and side chain protecting gp.

Esp. the method is used to make cpd. PyroGlu-Phe-gPhe-mGly -Leu-Met-NH₂ (Ia) (gPhe is gem-diaminophenylalanyl; mGly is malonyl).

Since (III) converts amido gps. on the resin, the synthesis can be done entirely in the solid phase. The method is simple and rapid;

suitable

for automation and avoids the losses associated with usual isolation and purification stages. (I) have biological activity equal or better than

tht

of their natural analogues and will improved resistance to enzymatic hydrolysis.

0/0

ACCESSION NUMBER: 1984-012770 [03] WPIDS

DOC. NO. CPI: C1984-005381

TITLE: Totally solid phase synthesis of peptide(s) - contg.

retro-inverted peptide bond,

using crosslinked sarcosinyl copolymer as support.

DERWENT CLASS: A96 B04

INVENTOR(S): PESSI, A; PINORI, M; VERDINI, A S; VISCOMI, G C

PATENT ASSIGNEE(S): (ANIS) ANIC SPA; (ASRN) ASSORENI; (ENIE) ENICHEM SPA

COUNTRY COUNT: 11

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 97994	A	19840111	(198403)*	EN	29
R: AT BE CH DE FR GB LI LU NL SE					
EP 97994	B	19870930	(198739)	EN	
R: AT BE CH DE FR GB LI LU NL SE					
DE 3373908	G	19871105	(198745)		
IT 1190891	B	19880224	(199050)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 97994	A	EP 1983-200889	19830617

PRIORITY APPLN. INFO: IT 1982-22046 19820624

L1 ANSWER 25 OF 28 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

TI **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraines and angina pectoris.

AN 2000-400037 [34] WPIX

AB WO 200031123 A UPAB: 20000718

NOVELTY - A **retro-inverted peptide** (I) or a derivative of it, which specifically binds to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the

following:

- (1) a **retro-inverted peptide** (II) which enhances delivery of an active agent across the gastro-intestinal tract into the systemic, portal or hepatic circulation;
- (2) a composition, comprising (I) or (II), bound to a material comprising an active agent used to treat a mammalian disease or disorder;
- (3) a composition, comprising a chimeric protein bound to a material comprising an active agent used to treat a mammalian disease or disorder, the protein comprises ZElan 144, ZElan 145 or ZElan 146, or a binding portion of them fused via a covalent bond to a second protein;
- (4) a composition, comprising (I) or (II) bound to a drug containing particle;
- (5) a pharmaceutical composition, comprising the composition of (2) in a carrier for use in vivo in humans;
- (6) an antibody, or a fragment of it, capable of immunospecifically binding (I) or (II);
- (7) a composition comprising (I) or (II) coated onto, absorbed onto or covalently bonded to, the surface of a nano- or microparticle; and
- (8) a nano- or microparticle formed from (I) or (II).

ACTIVITY - Hypotensive; antidiabetic; osteopathic; hemostatic; antianemic; cytostatic; antimigraine; antianginal.

MECHANISM OF ACTION - The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation.

USE - The gastrointestinal agents are used to facilitate transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation (claimed). The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraine, and angina pectoris (claimed). The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent.

The antibodies can be used for imaging peptides after in vivo administration, to monitor treatment efficacy, to measure peptide levels in physiological samples, and in diagnostic methods.

ADVANTAGE - None given.

Dwg. 0/2

ACCESSION NUMBER: 2000-400037 [34] WPIX
DOC. NO. CPI: C2000-120829
TITLE: **Retro-inverted peptide** used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, hemophilia, anemia, cancer, migraines and angina pectoris.
DERWENT CLASS: B04
INVENTOR(S): O'MAHONY, D J
PATENT ASSIGNEE(S): (ELAN-N) ELAN CORP PLC
COUNTRY COUNT: 91
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 2000031123	A2	20000602	(200034)*	EN	36
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ TZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES					
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS					
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL					
TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
AU 2000011744	A	20000613	(200043)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000031123	A2	WO 1999-IE117	19991119
AU 2000011744	A	AU 2000-11744	19991119
EP 1131344	A2	EP 1999-972640	19991119
		WO 1999-IE117	19991119

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000011744	A Based on	WO 200031123
EP 1131344	A2 Based on	WO 200031123

PRIORITY APPLN. INFO: US 1998-109038P 19981119

L1 ANSWER 26 OF 28 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
 TI Retro-inverted tri peptide cpds. - useful as hypotensive tranquillising and analgesic agents.
 AN 1986-286129 [44] WPIX
 AB EP 199379 A UPAB: 19930922
 Tripeptides with at least a **retro-inverted peptide** bond, pharmaceutically acceptable basic salts, esters or alkyl amides, of formula (I) are new (where Q1 and Q2 = -CONH- or -NHCO-, at least 1 being -NHCO-; R1 is H, 1-7C alkyl, aryl, hydroxyalkyl, hydroxyarylalkyl, guanidylalkyl, aminoalkyl, alkoxyalkyl, acylaminoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl, alkylmercaptoalkyl, carbamoylalkyl, carboxyalkyl, alkylcarbamoylalkyl or alkoxy-carbonylalkyl; R2 is p-hydroxybenzyl, benzyl or a gp. of formula (II); Z is OH, OR3, NH2 or NHR3; and R3 is 1-10C alkyl).

USE/ADVANTAGE - (I) are retro-inverse analogues of Glp-Leu-Trp-OH with hypotensive, tranquilliser and analgesic activities and with reduced tendency to inactivation by circulating peptidase enzymes. Hypotensive doses are e.g. 0.1-400, pref. 2-300 mg/kg/day, pref. in 2-4 units. Admin. may be p.o. or parenterally.

0/0

ABEQ EP 199379 B UPAB: 19930922
 Tripeptide with at least a retro-inverted peptidic bond, its pharmaceutically acceptable basic salts, esters or alkyl amides, definable by means of the following general formulae; Ia, Ib, Ic; R1 represents a hydrogen atom, an alkyl group with a maximum of 7 carbon atoms, an aryl, hydroxyalkyl or hydroxyarylalkyl, guanidylalkyl, amino-alkyl, alkyloxy-alkyl, acylamino-alkyl, imidazolylalkyl, indolyl-alkyl, mercapto-alkyl, alkylmercaptoalkyl, carbamoylalkyl, carboxyalkyl, alkyl-carbamoylalkyl or alky-loxy-carbonylalkyl group; R2 represents a gp. (i), (ii) or (iii) group; Z represents an OH, OR3, NH2, NHR3 group, wherein R3 represents an alkyl group with a number of carbon atoms comprised within the range of from 1 to 10.

ABEQ US 4748155 A UPAB: 19930922
 Tripeptides of formulae (I), (II) and (III) are claimed, where R1 is -CH2-CH(CH3)2, -CH(CH3)2 or -CH(CH3)CH2CH3; R2 is (p-hydroxy)benzyl or a gp. of formula (IV), and Z is OH, OR3 NH2, or NHR3, where R3 is 1-10C alkyl.

USE/ADVANTAGE - (I) is used to treat hypertension, anxiety and pain. They are less labile than prior tripeptides used for this purpose.

ACCESSION NUMBER: 1586-286129 [44] WPIX
 DOC. NO. CPI: 086-123788
 TITLE: Retro-inverted tri peptide cpds. - useful as hypotensive
 tranquillising and analgesic agents.
 DERWENT CLASS: B05
 INVENTOR(S): DELUCA, G; DISTAZIO, G; POLITI, V; SISTO, A; VERDINI, A
 S; VIRDIA, A
 PATENT ASSIGNEE(S): (ENIE) ENIRICERCHE SPA; (POLI-N) POLIFARMA SPA
 COUNTRY COUNT: 7
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 199379	A	19861029	(198644)*	EN	18
R: DE FR GB					
JP 61233665	A	19861017	(198648)		
US 4748155	A	19880531	(198824)		
EP 199379	B	19901003	(199040)		
R: DE FR GB					
IT 1184164	B	19871022	(199041)		
DE 3674623	G	19901108	(199046)		
JP 06088968	B2	19941109	(199443)		13

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 199379	A	EP 1986-200345	19860307
JP 61233665	A	JP 1986-59653	19860319
US 4748155	A	US 1986-838120	19860310
JP 06088968	B2	JP 1986-59653	19860319

FILING DETAILS:

PATENT NO	KIND	PATENT NO
JP 06088968	B2 Based on	JP 61233665

PRIORITY APPLN. INFO: IT 1985-19961 19850319

L1 ANSWER 27 OF 28 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD
 TI New retro-inverted analogues of bradykinin potentiator penta peptide -
 useful as prolonged action antihypertensives and diagnostic agents.
 AN 1986-198158 [31] WPIX
 AB EP 185433 A UPAB: 19930922
 Retro-inverted peptides of formula (I) useful as anti-hypertensives and
 diagnostics are new. R2, R3 = D-amino acid residues; R1 = side-chain of
 an amino acid residue present in a natural peptide or its analogue; A = H,
 1-7C alkyl, aryl, aralkyl or hydroxyalkyl; B = H, 1-7C alkyl, aryl,
 aralkyl, or OH-, guanidyl-, amino-, alkoxy-, acylamino-, imidazolyl-,
 indolyl-, SH-, alkylthio-, CONH2-, COOH-, alkylcarbonyl or
 alkoxy carbonyl-alkyl; or A+B = (CH2)m, in which one of the C atoms is
 directly bonded to PhCH2O or PhS; m = 3 or 4; Z = OH, alkoxy or NH2.
 (I) in which R1 = Me, R2 = D-Phe, R3 = D-Lys and NA-CHB-COZ =
 Pro(4-allo-S-Ph)-OH, in (S)- or (R)-forms, is specifically claimed.
 USE/ADVANTAGE - (I) are analogues of bradykinin potentiator
 pentapeptide and they inhibit angiotensin-converting enzyme and have more
 prolonged activity in vivo. They are therefore useful as
 antihypertensives
 and diagnostic agents.
 0/0
 ABEQ US 4713367 A UPAB: 19930922
 Partially retroinverso peptides of formula (I), analogues of bradykinin

potentiating peptide (BPPalpha), and salts are new. In (I), R1 and R2 are each the side chain of one of corresp natural peptides; X is -X-Ph or O-CH2-Ph; Z is OH, alkoxy, NH2. Pref cpds are Glp-Lys-gPhe-mAla Pro (4-allo-S-Ph)-OH and Glp-Lys-gPhe-m(S) Ala-Pro (4-allo-S-Ph)-OH. (I) may be prepd e.g. by condensing N-mono-acetylated gem diamine cpd (II) with peptide (III).

USE - (I) are more stable angiotensin-converting enzyme inhibitors than natural ACE inhibitor and are used as antihypertensives at dosage e.g. 1-1000(2.5-100) mg/day.

ABEQ US 4728725 A UPAB: 19930922

Retro-inverted peptide analogues of Bradykinin Potentiator Pentapeptide (BPP5a) of formula (I) are new.

In (I), R3 is D-Lys; R2 is D-Phe; R1 is natural peptide amino acid side chain; A and B together are (CH2)m residue forming ring with bonded

N

or C atoms and with one C of (CH2)m-bridge directly bonded to O-Bz or S-Ph; m is 3 or 4; and Z is OH, alkylOH or NH2.

Esp. cpds. are (Ia) and (Ib). (I) may be prepd. e.g. by liq. phase condensation of (II) with (III) using condensation agents.

USE - (I) are mixed inhibitors of ACE, recognising both C and N terminals, the retro-inversion giving increased stability against peptidases, and are used as highly active antihypertensives and diagnostics.

ACCESSION NUMBER: 1986-198158 [31] WPIX

DOC. NO. CPI: C1986-085243

TITLE: New retro-inverted analogues of bradykinin potentiator penta peptide - useful as prolonged action antihypertensives and diagnostic agents.

DERWENT CLASS: B03 P24

INVENTOR(S): SISTO, A; VERDINI, A S; VIRDIA, A

PATENT ASSIGNEE(S): (ENIE) ENICHEM SPA; (ENIR-N) ENIRECERCHE SPA; (VEDU-N) VERDUCCI G SRL; (VERD-N) VERDUCCI SRL G

COUNTRY COUNT: 13

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 185433	A	19860625	(198631)*	EN	8
R: AT BE CH DE FR GB IT LI LU NL SE					
FR 2575048	A	19860627	(198632)		
JP 61155395	A	19860715	(198634)		
JP 62501610	W	19870702	(198732)		
US 4713367	A	19871215	(198806)		
US 4728725	A	19880301	(198812)		
IT 1178789	B	19870916	(199035)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 185433	A	EP 1985-202099	19851218
JP 61155395	A	JP 1985-289135	19851221
US 4713367	A	US 1986-821449	19860122
US 4728725	A	US 1985-811487	19851220

PRIORITY APPLN. INFO: IT 1984-24200 19841221

L1 ANSWER 28 OF 28 WPIX COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Totally solid phase synthesis of peptide(s) - contg. **retro-inverted peptide** bond, using crosslinked sarcosinyl copolymer as support.

AN 1984-012770 [03] WPIX

AB EP 97994 A UPAB: 19930925

The support comprises polydimethylacrylamide -co-acryloylsarcosine methyl ester crosslinked with N,N'-ethylene bis-acrylamide. The polypeptide (I) chain is constructed, starting from the C terminus, by condensation with amino acid and/or peptide derivs. and cpds. of formula (II) (Z and Z' are side chains present in naturally-occurring amino acids).

The cpd. I, I-bis(trifluoroacetyl) iodobenzene (III) is then used to convert terminal prim. carboxyamides to amino, and finally the entire peptide is released from the resin simultaneously with removal of amine and side chain protecting gp.

Esp. the method is used to make cpd. PyroGlu-Phe-gPhe-mGly -Leu-Met-NH₂ (Ia) (gPhe is gem-diaminophenylalanyl; mGly is malonyl).

Since (III) converts amide gps. on the resin, the synthesis can be done entirely in the solid phase. The method is simple and rapid;

suitable

for automation and avoids the losses associated with usual isolation and purification stages. (I) have biological activity equal or better than

tht

of their natural analogues and will improved resistance to enzymatic hydrolysis.

0/0

ABEQ EP 97994 B UPAB: 19930925

The support comprises polydimethylacrylamide -co-acryloylsarcosine methyl ester crosslinked with N,N'-ethylene bis-acrylamide. The polypeptide (I) chain is constructed, starting from the C terminus, by condensation with amino acid and/or peptide derivs. and cpds. of formula (II) (Z and Z' are side chains present in naturally-occurring amino acids).

The cpd. I, I-bis(trifluoroacetyl) iodobenzene (III) is then used to convert terminal prim. carboxyamides to amino, and finally the entire peptide is released from the resin simultaneously with removal of amine and side chain protecting gp.

Esp. the method is used to make cpd. PyroGlu-Phe-gPhe-mGly -Leu-Met-NH₂ (Ia) (gPhe is gem-diaminophenylalanyl; mGly is malonyl).

Since (III) converts amide gps. on the resin, the synthesis can be done entirely in the solid phase. The method is simple and rapid;

suitable

for automation and avoids the losses associated with usual isolation and purification stages. (I) have biological activity equal or better than

tht

of their natural analogues and will improved resistance to enzymatic hydrolysis.

0/0

ACCESSION NUMBER: 1984-012770 [03] WPIX

DOC. NO. CPI: C1984-005381

TITLE: Totally solid phase synthesis of peptide(s) - contg. **retro-inverted peptide** bond, using crosslinked sarcosinyl copolymer as support.

DERWENT CLASS: A96 B04

INVENTOR(S): PESSI, A; PINORI, M; VERDINI, A S; VISCOMI, G C

PATENT ASSIGNEE(S): (ANIS) ANIC SPA; (ASRN) ASSORENI; (ENIE) ENICHEM SPA

COUNTRY COUNT: 11

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 97994	A	19840111	(198403)*	EN	29
	R:	AT BE CH DE FR GB LI LU NL SE			
EP 97994	B	19870930	(198739)	EN	
	R:	AT BE CH DE FR GB LI LU NL SE			
DE 3373908	G	19871105	(198745)		
IT 1190891	B	19880224	(199050)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

EP 97994

A

EP 1983-200889

30617

PRIORITY APPLN. INFO: IT 1982-22046

19820624